X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PLETHICO PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PLETHICO PHARMA DR. REDDYS LAB/
PLETHICO PHARMA
 
P/E (TTM) x 22.1 -1.1 - View Chart
P/BV x 3.4 0.0 20,092.0% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 DR. REDDYS LAB   PLETHICO PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
PLETHICO PHARMA
Mar-14
DR. REDDYS LAB/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788395 706.0%   
Low Rs1,90231 6,075.7%   
Sales per share (Unadj.) Rs860.8604.4 142.4%  
Earnings per share (Unadj.) Rs57.132.5 175.7%  
Cash flow per share (Unadj.) Rs122.051.3 237.7%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs757.7473.6 160.0%  
Shares outstanding (eoy) m165.9134.08 486.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.70.4 772.6%   
Avg P/E ratio x41.16.6 626.2%  
P/CF ratio (eoy) x19.24.2 462.9%  
Price / Book Value ratio x3.10.5 687.7%  
Dividend payout %35.00-   
Avg Mkt Cap Rs m389,0347,262 5,356.8%   
No. of employees `00023.5NA-   
Total wages/salary Rs m32,1491,596 2,014.3%   
Avg. sales/employee Rs Th6,070.8NM-  
Avg. wages/employee Rs Th1,366.6NM-  
Avg. net profit/employee Rs Th402.5NM-  
INCOME DATA
Net Sales Rs m142,81020,598 693.3%  
Other income Rs m1,552386 401.7%   
Total revenues Rs m144,36220,984 688.0%   
Gross profit Rs m23,5122,818 834.5%  
Depreciation Rs m10,772642 1,677.1%   
Interest Rs m7881,593 49.5%   
Profit before tax Rs m13,504969 1,394.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380-138 -3,165.2%   
Profit after tax Rs m9,4681,107 855.4%  
Gross profit margin %16.513.7 120.4%  
Effective tax rate %32.4-14.3 -227.0%   
Net profit margin %6.65.4 123.4%  
BALANCE SHEET DATA
Current assets Rs m104,98418,877 556.2%   
Current liabilities Rs m68,93811,896 579.5%   
Net working cap to sales %25.233.9 74.5%  
Current ratio x1.51.6 96.0%  
Inventory Days Days7436 206.9%  
Debtors Days Days104198 52.4%  
Net fixed assets Rs m104,3859,861 1,058.6%   
Share capital Rs m830341 243.6%   
"Free" reserves Rs m124,88612,331 1,012.8%   
Net worth Rs m125,71616,139 779.0%   
Long term debt Rs m25,0894,706 533.2%   
Total assets Rs m225,44333,146 680.2%  
Interest coverage x18.11.6 1,128.0%   
Debt to equity ratio x0.20.3 68.4%  
Sales to assets ratio x0.60.6 101.9%   
Return on assets %4.58.1 55.8%  
Return on equity %7.56.9 109.8%  
Return on capital %9.712.3 79.0%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m72,6234,402 1,649.6%   
Fx outflow Rs m18,9163,184 594.1%   
Net fx Rs m53,7071,219 4,407.6%   
CASH FLOW
From Operations Rs m18,0302,437 739.7%  
From Investments Rs m-14,883-6,265 237.6%  
From Financial Activity Rs m-4,4402,490 -178.3%  
Net Cashflow Rs m-1,236-1,337 92.4%  

Share Holding

Indian Promoters % 25.5 82.7 30.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.3 125.6%  
FIIs % 35.3 5.5 641.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 7.5 204.0%  
Shareholders   75,885 10,665 711.5%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  TORRENT PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 491 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

After opening the day marginally lower, share markets in India witnessed negative trading activity throughout the day and ended deep in the red.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

FM Nirmala Sitharaman Inherits an Economy Facing a Number of Headwinds(Sector Info)

Jun 4, 2019

The Indian economy is in a major slowdown. Will the new finance minister, Nirmala Sitharaman bring the much-needed reforms?

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 17, 2019 03:33 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS